ExpreS2ion to Present in Upcoming Investor and Scientific Events
Hørsholm, Denmark, 9 January 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in two key upcoming events: PepTalk – the Annual Protein Science and Production Week in San Diego, USA, and an Institutional Investor Seminar hosted by HC Andersen Capital in Copenhagen, Denmark.
These events represent important opportunities to showcase ExpreS2ion’s innovative technology platform and exciting development pipeline to scientific and investment audiences. More details, including event registration information, are available on the Company’s website and via the links below. To arrange a meeting at either event, please contact us at info@expreS2ionbio.com.
13-16 January 2025 | PepTalk - Protein Science and Production Week
San Diego, California, USA
PepTalk is a leading conference focused on advancing biotherapeutic discovery and development. On 16 January at 11:30 AM PST, ExpreS2ion’s VP of R&D and Technology, Max Søegaard, will present a talk titled “Advancements in VLP Technology: From Pandemic Countermeasures to Broad-Spectrum Applications in Vaccine Development.” Additional details are available on the Peptalk website.
16 January 2025 | Institutional Investor Seminar
Copenhagen, Denmark
ExpreS2ion’s CEO, Bent Frandsen, will present at an Institutional Investor Seminar hosted by HC Andersen Capital. The presentation will focus on ES2B-C001, ExpreS2ion’s novel therapeutic breast cancer vaccine, which recently received Clinical Trial Application (CTA) approval from Austrian regulatory authorities for a Phase I clinical trial. Nordic institutional investors interested in attending are encouraged to contact HC Andersen Capital for participation details.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.